
Loading, please wait...

Loading, please wait...

Recent advancements in metabolic engineering have simplified fungal metabolite production by utilizing viral 2A peptides within the yeast Yarrowia lipolytica. Filamentous fungi remain a primary source of bioactive secondary metabolites. However, scientists often face hurdles in cultivation and genetic engineering when working with these organisms. To overcome these challenges, researchers are turning to heterologous hosts like Y. lipolytica, which is a robust and safe platform for biomanufacturing.
The study highlights the potential of polycistronic expression strategies to manage multigene biosynthetic clusters. Specifically, the team compared several viral 2A peptides to identify which sequences offer the highest cleavage efficiency. They discovered that non-canonical peptides, such as PNPV2A1, perform exceptionally well in Yarrowia lipolytica. Consequently, this sequence allowed the researchers to reconstruct the Aspergillus hancockii pathway. This setup successfully produced m-cresol, reaching a significant titer of 306 mg/L. Therefore, these tools streamline the complex assembly of metabolic pathways.
Moreover, the use of bicistronic reporters demonstrated that polycistronic setups can compete effectively with traditional monocistronic methods. Although monocistronic expression sometimes yields higher titers, the 2A peptide approach offers a more compact and efficient genetic toolkit. Additionally, this method reduces the labor-intensive steps required for multi-gene integration. As a result, the discovery of new natural products becomes faster and more scalable. Furthermore, expanding the arsenal of 2A peptides provides metabolic engineers with more precise control over gene ratios within a single expression cassette.
2A peptides are short viral sequences that enable the production of multiple distinct proteins from a single messenger RNA molecule. They allow for the co-expression of several genes in a simplified genetic architecture.
Yarrowia lipolytica is an oleaginous yeast with "Generally Recognized as Safe" (GRAS) status. Its unique ability to manage high flux toward lipid-based precursors makes it ideal for producing complex bioactive molecules.
By streamlining the expression of biosynthetic gene clusters, researchers can more easily produce and identify new fungal metabolites. This efficiency accelerates the search for novel antibiotics, antifungals, and other pharmaceutical compounds.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References
Bejenari M et al. 2A peptides enable simplified discovery and heterologous production of fungal bioactive metabolites in Yarrowia lipolytica. Appl Microbiol Biotechnol. 2026 Mar 22. doi: 10.1007/s00253-026-13797-y. PMID: 41865221.
Nielsen J. Biosynthesis of fungal secondary metabolites: Commercial aspects. Drug Discovery Today. 2023;28(4):103-112.
Wang G et al. Engineering Yarrowia lipolytica for advanced biomanufacturing. Trends in Biotechnology. 2024;42(2):185-198.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A new study identifies non-canonical 2A peptides that significantly improve the polycistronic expression of fungal metabolites in Yarrowia lipolytica....
5 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today